AGEN Agenus Inc

Price (delayed)

$1.49

Market cap

$495.44M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.78

Enterprise value

$395.2M

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the ...

Highlights
The EPS is up by 8% since the previous quarter
Agenus's revenue has plunged by 67% YoY but it has increased by 9% from the previous quarter
The gross profit has plunged by 70% YoY
The quick ratio has decreased by 47% YoY and by 21% from the previous quarter

Key stats

What are the main financial stats of AGEN
Market
Shares outstanding
332.51M
Market cap
$495.44M
Enterprise value
$395.2M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
4.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.03
Earnings
Revenue
$98.02M
EBIT
-$158.21M
EBITDA
-$151.27M
Free cash flow
-$206.44M
Per share
EPS
-$0.78
Free cash flow per share
-$0.73
Book value per share
-$0.2
Revenue per share
$0.35
TBVPS
$1.36
Balance sheet
Total assets
$413.56M
Total liabilities
$468.46M
Debt
$78.43M
Equity
-$61.28M
Working capital
$24.17M
Liquidity
Debt to equity
-1.28
Current ratio
1.13
Quick ratio
1.04
Net debt/EBITDA
0.66
Margins
EBITDA margin
-154.3%
Gross margin
89.2%
Net margin
-224.5%
Operating margin
-183.9%
Efficiency
Return on assets
-50.6%
Return on equity
N/A
Return on invested capital
-172.4%
Return on capital employed
-70.4%
Return on sales
-161.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AGEN stock price

How has the Agenus stock price performed over time
Intraday
0.68%
1 week
-12.35%
1 month
-24.75%
1 year
-46.59%
YTD
-37.92%
QTD
-37.92%

Financial performance

How have Agenus's revenue and profit performed over time
Revenue
$98.02M
Gross profit
$87.46M
Operating income
-$180.24M
Net income
-$220.07M
Gross margin
89.2%
Net margin
-224.5%
The gross profit has plunged by 70% YoY
Agenus's revenue has plunged by 67% YoY but it has increased by 9% from the previous quarter
The gross margin has decreased by 10% YoY and by 7% from the previous quarter
AGEN's operating margin is up by 7% from the previous quarter

Growth

What is Agenus's growth rate over time

Valuation

What is Agenus stock price valuation
P/E
N/A
P/B
N/A
P/S
4.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.03
The EPS is up by 8% since the previous quarter
Agenus's revenue has plunged by 67% YoY but it has increased by 9% from the previous quarter
The stock's price to sales (P/S) is 37% less than its 5-year quarterly average of 6.8

Efficiency

How efficient is Agenus business performance
Agenus's ROIC has plunged by 169% YoY but it has increased by 11% from the previous quarter
Agenus's return on assets has decreased by 6% QoQ
The return on sales is up by 5% since the previous quarter

Dividends

What is AGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AGEN.

Financial health

How did Agenus financials performed over time
AGEN's total assets is 12% lower than its total liabilities
Agenus's current ratio has decreased by 47% YoY and by 22% QoQ
The quick ratio has decreased by 47% YoY and by 21% from the previous quarter
The debt to equity has dropped by 176% year-on-year but it has surged by 67% since the previous quarter
Agenus's debt has increased by 35% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.